5:53 PM
 | 
Jul 17, 2013
 |  BC Extra  |  Company News

Alkermes showcases three new programs

Alkermes plc (NASDAQ:ALKS) unveiled three new preclinical programs at its R&D day on Wednesday: small molecule prodrugs of monomethyl fumarate (MMF) for multiple sclerosis (MS); ALK 7106,...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >